Krystal Biotech Shares Surge on Expanded FDA Approval

Expanded Label Unlocks Major Market Opportunity

Gene therapy specialist Krystal Biotech has achieved a significant regulatory milestone that is driving substantial investor interest. The company’s flagship treatment, VYJUVEK, has received a broadened approval from the U.S. Food and Drug Administration that dramatically increases its commercial potential and simplifies its administration.

The FDA’s updated approval represents a fundamental shift for VYJUVEK’s market positioning. Treatment can now begin immediately after birth, removing all previous age restrictions and substantially widening the eligible patient population. More significantly, the therapy can now be administered in home settings by patients and their caregivers rather than requiring clinical visits.